Regorafenib in Patients With Refractory Primary Bone Tumors
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
The aim of the project is to improve treatment outcomes in patients with primary malignant
bone tumors, refractory to standard therapy, by increasing the availability of advanced
therapy, as well as to develop treatment options using advanced molecular diagnostics for
patients who have not responded to the standard therapeutic regimen, and to introduce modern
diagnostics for risk stratification and for the use in molecularly targeted therapies.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Institute of Mother and Child, Warsaw, Poland
Collaborator:
Maria Sklodowska-Curie National Research Institute of Oncology